Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris
Launched by GALDERMA R&D · Oct 27, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
The main objective of this study is to evaluate subject satisfaction with the treatment regimen comprising Benzaknen® 5% Gel in association with 2 cosmetic products including a foam soap, Dermotivin® Soft Liquid soap, and a non comedogenic moisturizer, Cetaphil® Dermacontrol Moisturizer SPF30, in patients with mild to moderate acne, after 12 weeks of treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female subject of any ethnic background of 12 years or older.
- • Subject with mild or moderate facial acne vulgaris defined as an Investigator Global Assessment (IGA) score at 2 or 3 on a 0-4 scale.
- • Subject with any skin phototype according to T.B. Fitzpatrick skin phototype definitions.
- Exclusion Criteria:
- • Subject with severe acne (IGA\>3) with nodules, cysts, scars or extra-facial lesions,
- • Female subject who is pregnant, lactating or planning a pregnancy during the study,
- • Subject susceptible to take a corticosteroid treatment during the study except inhaled or topic when needed to treat a condition outside the face,
Trial Officials
Mi-Ran EGBERT, MD
Principal Investigator
Proinnovera GmbH
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Münster, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials